Abstract
Lentigo maligna (LM) is an in situ form of malignant melanoma, and surgical excision is often unsatisfactory. Imiquimod cream is an immune response modifier and induces a predominantly T-helper 1 type response.
| Original language | English |
|---|---|
| Pages (from-to) | 485-488 |
| Number of pages | 4 |
| Journal | The British journal of dermatology |
| Volume | 151 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Aug 2004 |
Keywords
- Aminoquinolines
- Hutchinson's Melanotic Freckle
- Antineoplastic Agents
- Humans
- Adult
- Treatment Outcome
- Aged
- Pilot Projects
- Middle Aged
- Skin Neoplasms
- Administration, Topical
Fingerprint
Dive into the research topics of 'A pilot study of treatment of lentigo maligna with 5% imiquimod cream'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver